Tolerabil ity of Oxal ipltin2based Adjuvant Chemotherapy in Colorectal Cancer Patients

Objective 　To analyze the tolerability of oxaliplatin2based adjuvant chemotherapy in colorectal cancer patient s. Methods 　Clinical data of 250 patient s who had received oxaliplatin2based adjuvant chem2 otherapy f rom November 2001 to J anuary 2008 in our hospital were analyzed ret rospectively. There were three different chemotherapy regimens. Bi2weekly oxaliplatin combined with continuous int ravenous in2 fused 5 fluorouracil (52Fu) and leucovorin (LV) ( FOL FOX4) 、t ri2weekly oxaliplatin combined with bolus 52Fu and LV(LOHP/ Fu/ LV) or orally capecitabine (XELOX) . Results 　Relative dose intensity of oxali2 platin were 99. 4 %、93. 3 % and 100. 5 % respectively in these three regimens. The median number of completed t reatment cycles were 8 、6 and 6. The most common cause for withdrawing f rom t reatment early was to be unable to tolerate the adverse effect s (AEs) . Nausea (88. 8 %) 、vomiting (45. 6 %) 、neu2 ropathy (71. 2 %) 、neut ropenia (38 %) and thrombocytopenia (55. 6 %) were the most f requent grade 3 or 4 AEs. Anaemia was more common in rectal cancer patient s than in colon cancer patient s. Conclusion 　Pa2 tient s in our hospital who received oxaliplatin2based adjuvant chemotherapy were less tolerable than in western count ries. It is necessary to us to expect the survival data to show if there are any difference be2 tween our patient s and westerns.